Dipatimenti Yapadziko Lonse

Pa Julayi 17, Center for Drug Evaluation (CDE) ya National Medical Products Administration (NMPA) idalengeza kuti pempho lotsatsa la Trastuzumab Deruxtecan (Enhertu®) lochizira khansa ya m'mimba lavomerezedwa mwalamulo ndi NMPA. Pempho ili ndi logwirizana...Werengani zambiri»

Posachedwapa, Ascentage Pharma yalengeza kuti mankhwala ake atsopano a Bcl-2 selective inhibitor lisaftoclax (APG-2575) avomerezedwa ndi China's National Medical Products Administration (NMPA) kuti athandize odwala akuluakulu omwe ali ndi matenda a chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)...Werengani zambiri»

Posachedwapa, GenFleet Therapeutics yalengeza kuti Pharmaceutical Administration Bureau (ISAF) ya Macau Special Administrative Region ku China yavomereza Dupert® (fulzerasib, GFH925/IBI351) kuti ichiritse odwala omwe ali ndi khansa ya m'mapapo ya non-small cell (NSCLC) yomwe ili ndi KRAS G12C mutati...Werengani zambiri»

Pa June 30, mankhwala oletsa MET a Avistone omwe adapangidwa paokha, Vebreltinib, adalandira chilolezo kuchokera ku National Medical Products Administration (NMPA) yaku China kuti achiritse odwala omwe ali ndi khansa ya m'mapapo yopanda maselo ang'onoang'ono (NSCLC) yomwe ili ndi MET amplifies...Werengani zambiri»

Pa June 30, 2025, HUTCHMED yalengeza kuti New Drug Application (NDA) yophatikiza ORPATHYS (savolitinib) ndi TAGRISSO (osimertinib) yavomerezedwa ndi China National Medical Products Administration (NMPA) kuti ichiritse odwala omwe ali ndi matenda a metastasis m'deralo.Werengani zambiri»

Pa June 30, tsamba lovomerezeka la National Medical Products Administration (NMPA) linalengeza kuti Anlotinib, mankhwala atsopano a Class 1 omwe adapangidwa ndi Chia Tai Tianqing, avomerezedwa ndi chizindikiro chatsopano ku China: mankhwala ophatikizana ndi chemotherapy pochiza odwala oyamba ...Werengani zambiri»

Pa June 26, 2025, CARsgen yalengeza kuti National Medical Products Administration (NMPA) ya ku China yavomereza New Drug Application (NDA) ya satricabtagene autoleucel ("satri-cel", CT041) (mankhwala a autologous CAR T-cell omwe amatsutsana ndi puloteni Claudin18.2) pochiza Claudin...Werengani zambiri»

Pa June 19, Center for Drug Evaluation (CDE) ya National Medical Products Administration (NMPA) idalengeza kuti jakisoni wa LM-108 wa Livzon Pharmaceutical waperekedwa kuti uphatikizidwe mu njira yopangira chithandizo. Kuphatikiza kwa jakisoni wa Kefeqibai monoclonal antibody (LM-1...Werengani zambiri»

Pa June 19, Center for Drug Evaluation (CDE) ya National Medical Products Administration (NMPA) idalengeza kuti IBI343 ya Innovent Biologics yaperekedwa kuti iphatikizidwe mu pulogalamu yodziwika bwino ya chithandizo, yopangidwira kuchiza matenda a khansa omwe afalikira m'deralo kapena omwe afalikira m'thupi.Werengani zambiri»

Pa June 6, magazini ya zachipatala yapadziko lonse ya Journal of Hematology & Oncology inafalitsa zotsatira za kafukufuku wa gawo loyamba/lachiwiri (KL264-01/MK-2870-001) wa TROP2 ADC sacituzumab tirumotecan (sac-TMT) watsopano ngati mankhwala amodzi a khansa yoopsa yomwe singachiritsidwe m'deralo kapena yofalikira kwambiri yomwe singathe kuchiritsidwa.Werengani zambiri»

Pa June 10, Center for Drug Evaluation (CDE) ya National Medical Products Administration (NMPA) idalengeza kuti Trastuzumab Deruxtecan (T-DXd, DS-8201a) ikuperekedwa kuti iwunikidwenso patsogolo pochiza odwala akuluakulu omwe ali ndi matenda am'mimba omwe ali ndi HER2 m'malo mwake kapena omwe ali ndi matenda enaake a m'mimba ...Werengani zambiri»

Posachedwapa, Merck & Co., Inc. (Merck) yalengeza kuti mankhwala ake oletsa PD-1, pembrolizumab, avomerezedwa ndi National Medical Products Administration (NMPA) yaku China kuti agwiritsidwe ntchito limodzi ndi lenvatinib ndi transarterial chemoembolization (TACE) pochiza odwala omwe ali ndi kachilombo...Werengani zambiri»